Literature DB >> 10498607

Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.

S Hashimoto1, A Iwamatsu, M Ishiai, K Okawa, T Yamadori, M Matsushita, Y Baba, T Kishimoto, T Kurosaki, S Tsukada.   

Abstract

Bruton's tyrosine kinase (Btk) is a critical component in the B-cell antigen receptor (BCR)-coupled signaling pathway. Its deficiency in B cells leads to loss or marked reduction in the BCR-induced calcium signaling. It is known that this BCR-induced calcium signaling depends on the activation of phospholipase Cgamma (PLCgamma), which is mediated by Btk and another tyrosine kinase Syk and that the SH2 and pleckstrin homology (PH) domains of Btk play important roles in this activation process. Although the importance of the PH domain of Btk has been explained by its role in the membrane targeting of Btk, the functional significance of the SH2 domain in the calcium signaling has remained merely a matter of speculation. In this report, we identify that one of the major Btk-SH2 domain-binding proteins in B cells is BLNK (B-cell linker protein) and present evidences that the interaction of BLNK and the SH2 domain of Btk contributes to the complete tyrosine phosphorylation of PLCgamma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498607

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  BLNK mediates Syk-dependent Btk activation.

Authors:  Y Baba; S Hashimoto; M Matsushita; D Watanabe; T Kishimoto; T Kurosaki; S Tsukada
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 2.  Adapters in lymphocyte signaling.

Authors:  Albrecht Leo; Jürgen Wienands; Gottfried Baier; Vaclav Horejsi; Burkhart Schraven
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

3.  BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins.

Authors:  Christopher W Chiu; Mark Dalton; Masamichi Ishiai; Tomohiro Kurosaki; Andrew C Chan
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

Review 4.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 5.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 6.  Ligand-independent signaling during early avian B cell development.

Authors:  Kelly A Pike; Michael J H Ratcliffe
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Subcellular localization of Grb2 by the adaptor protein Dok-3 restricts the intensity of Ca2+ signaling in B cells.

Authors:  Björn Stork; Konstantin Neumann; Ingo Goldbeck; Sebastian Alers; Thilo Kähne; Michael Naumann; Michael Engelke; Jürgen Wienands
Journal:  EMBO J       Date:  2007-02-08       Impact factor: 11.598

8.  Conformational snapshots of Tec kinases during signaling.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  The Dok-3/Grb2 protein signal module attenuates Lyn kinase-dependent activation of Syk kinase in B cell antigen receptor microclusters.

Authors:  Marion Lösing; Ingo Goldbeck; Birgit Manno; Thomas Oellerich; Tim Schnyder; Hanibal Bohnenberger; Björn Stork; Henning Urlaub; Facundo D Batista; Jürgen Wienands; Michael Engelke
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

10.  The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.

Authors:  Konstanze Pechloff; Julian Holch; Uta Ferch; Marc Schweneker; Kristina Brunner; Markus Kremer; Tim Sparwasser; Leticia Quintanilla-Martinez; Ursula Zimber-Strobl; Berthold Streubel; Andreas Gewies; Christian Peschel; Jürgen Ruland
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.